EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Evaluation of secretome biomarkers in glioblastoma cancer stem cells: A bioinformatics analysis

Ehsan Jangholi iD, Hoda Ahmari Tehran, Afsaneh Ghasemi, Mohammad Hoseinian, Sina Firoozi, Seyed Mohammad Ghodsi, Mona Tamaddon, Ahmad Bereimipour, Mahmoudreza Hadjighassem

Cancer Reports · 2024

DOI: 10.1002/cnr2.2080 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Reports, 2024. Verfasst von Ehsan Jangholi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Brain and Spinal Cord Injury Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran. Hauptthemen laut MEDLINE: Glioblastoma, Biomarkers, Tumor, Computational Biology, Neoplastic Stem Cells. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Brain and Spinal Cord Injury Research Center, Neuroscience Institute, Tehran University of Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Glioblastoma (GBM) is a malignant brain tumor that frequently occurs alongside other central nervous system (CNS) conditions. The secretome of GBM cells contains a diverse array of proteins released into the extracellular space, influencing the tumor microenvironment. These proteins can serve as potential biomarkers for GBM due to their involvement in key biological processes, exploring the secretome biomarkers in GBM research represents a cutting‐edge strategy with significant potential for advancing diagnostic precision, treatment monitoring, and ultimately improving outcomes for patients with this challenging brain cancer.

Aim

This study was aimed to investigate the roles of secretome biomarkers and their pathwayes in GBM through bioinformatics analysis. Methods and Results Using data from the Gene Expression Omnibus and the Cancer Genome Atlas datasets—where both healthy and cancerous samples were analyzed—we used a quantitative analytical framework to identify differentially expressed genes (DEGs) and cell signaling pathways that might be related to GBM. Then, we performed gene ontology studies and hub protein identifications to estimate the roles of these DEGs after finding disease‐gene connection networks and signaling pathways. Using the GEPIA Proportional Hazard Model and the Kaplan–Meier estimator, we widened our analysis to identify the important genes that may play a role in both progression and the survival of patients with GBM. In total, 890 DEGs, including 475 and 415 upregulated and downregulated were identified, respectively. Our results revealed that SQLE , DHCR7 , delta‐1 phospholipase C ( PLCD1 ), and MINPP1 genes are highly expressed, and the Enolase 2 ( ENO2 ) and hexokinase‐1 ( HK1 ) genes are low expressions.

Conclusion

Hence, our findings suggest novel mechanisms that affect the occurrence of GBM development, growth, and/or establishment and may also serve as secretory biomarkers for GBM prognosis and possible targets for therapy. So, continued research in this field may uncover new avenues for therapeutic interventions and contribute to the ongoing efforts to combat GBM effectively.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaBiomarkers, TumorComputational BiologyNeoplastic Stem CellsBrain NeoplasmsGene Expression Regulation, NeoplasticHumansSecretomeGene Expression ProfilingSignal TransductionPrognosisGene Regulatory NetworksProtein Interaction MapsTumor Microenvironment

Stichwörter der Autor:innen

bioinformatics analysisbiomarkercancer stem cellsgene expression profilesglioblastoma

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Brain and Spinal Cord Injury Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran.
  • Department of Neurosurgery, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.
  • Department of Medical Education, Qom University of Medical Sciences, Qom, Iran.
  • Department of Public Health, School of Health, Fasa University of Medical Sciences, Fasa, Iran.
  • School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran.
  • Chronic Disease Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.

ORCID-Profile: Ehsan Jangholi

Förderung

  • Brain and Spinal Cord Injury Research Center, Neuroscience Institute, Tehran University of Medical Sciences

Zitieren

APA

Jangholi, E., Tehran, H. A., Ghasemi, A., Hoseinian, M., Firoozi, S., Ghodsi, S. M., Tamaddon, M., Bereimipour, A., & Hadjighassem, M. (2024). Evaluation of secretome biomarkers in glioblastoma cancer stem cells: A bioinformatics analysis. Cancer Reports. https://doi.org/10.1002/cnr2.2080

Vancouver

Jangholi E, Tehran HA, Ghasemi A, Hoseinian M, Firoozi S, Ghodsi SM, et al. Evaluation of secretome biomarkers in glioblastoma cancer stem cells: A bioinformatics analysis. Cancer Reports. 2024. doi:10.1002/cnr2.2080

BibTeX
@article{Jangholi2024,
  author = {Jangholi, Ehsan and Tehran, Hoda Ahmari and Ghasemi, Afsaneh and Hoseinian, Mohammad and Firoozi, Sina and Ghodsi, Seyed Mohammad and Tamaddon, Mona and Bereimipour, Ahmad and Hadjighassem, Mahmoudreza},
  title = {Evaluation of secretome biomarkers in glioblastoma cancer stem cells: A bioinformatics analysis},
  journal = {Cancer Reports},
  year = {2024},
  doi = {10.1002/cnr2.2080}
}
Kostenlos starten →